LEXEO THERAPEUTICS INC (LXEO) Stock Analyst Ratings
USA - NASDAQ:LXEO - US52886X1072 - Common Stock
9.445 USD
+0.41 (+4.48%)
ChartMill assigns a Buy % Consensus number of 88% to LXEO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 21.29. This target is 125.44% above the current price.
LXEO was analyzed by 15 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about LXEO.
In the previous month the buy percentage consensus was at a similar level.
LXEO was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-15 | Guggenheim | Initiate | Buy |
| 2025-10-07 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-10-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-31 | Oppenheimer | Initiate | Outperform |
| 2025-05-30 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-05-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-25 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-03-24 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-01-21 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-13 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-11-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-30 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-13 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-15 | Chardan Capital | Maintains | Buy -> Buy |
LEXEO THERAPEUTICS INC / LXEO FAQ
Can you provide the average price target for LEXEO THERAPEUTICS INC stock?
15 analysts have analysed LXEO and the average price target is 21.29 USD. This implies a price increase of 125.44% is expected in the next year compared to the current price of 9.445.
What is the consensus rating for LXEO stock?
The consensus rating for LEXEO THERAPEUTICS INC (LXEO) is 88 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed LEXEO THERAPEUTICS INC (LXEO)?
The number of analysts covering LEXEO THERAPEUTICS INC (LXEO) is 15.